Temat: "Factor VIII" - OpacWWW

Skocz do pozycji: 41.

Tytuł:: Paradigm shifts in haemophilia A therapy with emicizumab prophylaxis in Asia.
Autorzy:: Sosothikul, Darintr
Moonla, Chatphatai; Pokaż więcej
Źródło:: Annals of the Academy of Medicine, Singapore. Nov2023, Vol. 52 Issue 11, p556-558. 3p.

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 42.

Tytuł:: Impact of aPTT reagents on measurement of a PEGylated recombinant FVIII (Adynovi ): A French multicentric field assay study.
Autorzy:: Ternisien C; Service d'Hématologie Hémostase, Hôtel Dieu, CHU de Nantes, Nantes, France.
Lasne D; Laboratoire d'hématologie générale, Hôpital Necker AP-HP, Paris, France.
Grand F; Service d'Hématologie Biologique, CHU de Poitiers, Poitiers, France.
Harzallah I; Service d'Hématologie Hémostase, Centre hospitalier de Mulhouse, Mulhouse, France.
Jeanpierre E; Pôle de Biologie Pathologie Génétique, CHRU de Lille, Lille, France.
Repesse Y; Service d'Hématologie Biologique, CHU de Caen, Caen, France.
Ryman A; Service d'Hématologie Biologique, CHU de Bordeaux, Bordeaux, France.
Sapin AF; Service d'Hématologie Biologique, CHU de Clermont Ferrand, Clermont-Ferrand, France.
Voisin S; Laboratoire d'Hématologie, Hôpital de Rangueil, CHU de Toulouse, Toulouse, France.
Nougier C; Service d'Hématologie Hémostase, Hospices Civils de Lyon, Lyon, France.
Pouplard C; Service d'Hématologie-Hémostase, Hôpital Trousseau, CHU de Tours, Tours, France.; EA 7501 Université François Rabelais, Tours, France.; Pokaż więcej
Corporate Authors:: French study group on laboratory management of bleeding disorders (BIMHO Group-GFHT)
Źródło:: International journal of laboratory hematology [Int J Lab Hematol] 2022 Apr; Vol. 44 (2), pp. e55-e59. Date of Electronic Publication: 2021 Sep 24.
Typ publikacji:: Letter
MeSH Terms:: Factor VIII*
Hemophilia A*/drug therapy
Humans ; Indicators and Reagents ; Partial Thromboplastin Time ; Polyethylene Glycols

Opinia redakcyjna

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 43.

Tytuł:: Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81-8973.
Autorzy:: Arvanitakis A; Department of Translational Medicine, Lund University, Malmö, Sweden.; Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.
Holme PA; Department of Haematology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Berntorp E; Department of Translational Medicine, Lund University, Malmö, Sweden.
Astermark J; Department of Translational Medicine, Lund University, Malmö, Sweden.; Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.; Pokaż więcej
Źródło:: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2022 Mar; Vol. 28 (2), pp. 223-229. Date of Electronic Publication: 2022 Jan 10.
Typ publikacji:: Journal Article
MeSH Terms:: Factor VIII*/pharmacokinetics
Hemophilia A*/drug therapy
Half-Life ; Hemarthrosis ; Humans ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 44.

Tytuł:: Ectopic Expression of FVIII in HPCs and MSCs Derived from hiPSCs with Site-Specific Integration of ITGA2B Promoter-Driven BDDF8 Gene in Hemophilia A.
Autorzy:: Zhao J; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Zhou M; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Wang Z; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Wu L; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Hu Z; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.
Liang D; Center for Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2022 Jan 06; Vol. 23 (2). Date of Electronic Publication: 2022 Jan 06.
Typ publikacji:: Journal Article
MeSH Terms:: Ectopic Gene Expression*
Promoter Regions, Genetic*
Factor VIII/*genetics
Hematopoietic Stem Cells/*metabolism
Hemophilia A/*genetics
Induced Pluripotent Stem Cells/*metabolism
Integrin alpha2/*genetics
Mesenchymal Stem Cells/*metabolism
Base Sequence ; DNA, Ribosomal/genetics ; Factor VIII/chemistry ; Factor VIII/metabolism ; Gene Targeting ; Genetic Loci ; Genetic Vectors/metabolism ; Humans ; Integrin alpha2/metabolism ; Megakaryocytes/metabolism ; Protein Domains ; Sequence Deletion ; Transcription Activator-Like Effector Nucleases/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 45.

Tytuł:: Serum TNF- α Level as a Possible Predictor of Inhibitor Levels in Severe Hemophilia A.
Autorzy:: Susanah S; Department of Child Health, Hematology-Oncology Division, Dr. Hasan Sadikin General Hospital/Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
Raspati H; Department of Child Health, Hematology-Oncology Division, Dr. Hasan Sadikin General Hospital/Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
Sari NM; Department of Child Health, Hematology-Oncology Division, Dr. Hasan Sadikin General Hospital/Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
Rakhmilla LE; Department of Public Health, Epidemiology and Biostatistic Division, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
Sribudiani Y; Department of Biomedical Sciences, Biochemistry and Molecular Biology Division, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.; Study Center of Medical Genetics, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
Moestopo O; Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
Sinaga P; Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
Idjradinata P; Department of Child Health, Hematology-Oncology Division, Dr. Hasan Sadikin General Hospital/Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.
Maskoen AM; Study Center of Medical Genetics, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, Indonesia.; Pokaż więcej
Źródło:: BioMed research international [Biomed Res Int] 2021 Nov 05; Vol. 2021, pp. 6483490. Date of Electronic Publication: 2021 Nov 05 (Print Publication: 2021).
Typ publikacji:: Journal Article
MeSH Terms:: Factor VIII/*immunology
Hemophilia A/*metabolism
Tumor Necrosis Factor-alpha/*genetics
Adolescent ; Biomarkers, Pharmacological/blood ; Child ; Child, Preschool ; Cross-Sectional Studies ; Factor VIII/genetics ; Factor VIII/metabolism ; Hemophilia A/drug therapy ; Humans ; Indonesia ; Infant ; Isoantibodies/immunology ; Male ; Polymorphism, Single Nucleotide/genetics ; Prognosis ; Risk Factors ; Tumor Necrosis Factor-alpha/blood ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 46.

Tytuł:: Recombinant factor VIII Fc for the treatment of haemophilia A.
Autorzy:: Hermans C; Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
Mancuso ME; Center for Thrombosis and Hemorrhagic Diseases, Humanitas Clinical and Research Center - IRCCS, Rozzano, Italy.
Nolan B; Children's Health Ireland at Crumlin, Dublin, Ireland.
Pasi KJ; Royal London Haemophilia Centre, Barts and the London School of Medicine and Dentistry, London, UK.; Pokaż więcej
Źródło:: European journal of haematology [Eur J Haematol] 2021 Jun; Vol. 106 (6), pp. 745-761. Date of Electronic Publication: 2021 Mar 31.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Factor VIII*/pharmacokinetics
Factor VIII*/therapeutic use
Hemophilia A*/blood
Hemophilia A*/drug therapy
Immunoglobulin Fc Fragments*/therapeutic use
Recombinant Fusion Proteins*/pharmacokinetics
Recombinant Fusion Proteins*/therapeutic use
Immune Tolerance/*drug effects
Clinical Trials as Topic ; Humans

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 47.

Tytuł:: Clinical outcomes after joint surgery in patients on turoctocog alfa pegol (N8-GP) prophylaxis: A post hoc analysis.
Autorzy:: Hampton K; Department of Cardiovascular Science, University of Sheffield, Sheffield, UK.
Tiede A; Department of Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany.
Shivamurthy S; Novo Nordisk, Bengaluru, India.
Chowdary P; Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK.; Pokaż więcej
Źródło:: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2022 Jan; Vol. 28 (1), pp. 158-165. Date of Electronic Publication: 2021 Nov 22.
Typ publikacji:: Clinical Trial; Journal Article
MeSH Terms:: Factor VIII*
Hemophilia A*/complications
Hemophilia A*/drug therapy
Hemarthrosis/etiology ; Hemarthrosis/prevention & control ; Hemorrhage/etiology ; Hemorrhage/prevention & control ; Humans

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 48.

Tytuł:: Four Decades of Carrier Detection and Prenatal Diagnosis in Hemophilia A: Historical Overview, State of the Art and Future Directions.
Autorzy:: Dardik R; National Hemophilia Center, Sheba Medical Center, Ramat Gan 52621, Israel.; Amalia Biron Research Institute of Thrombosis and Hemostasis, Sackler School of Medicine, Tel Aviv University, Tel Aviv 52621, Israel.
Janczar S; Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, 90-419 Lodz, Poland.
Lalezari S; National Hemophilia Center, Sheba Medical Center, Ramat Gan 52621, Israel.; Amalia Biron Research Institute of Thrombosis and Hemostasis, Sackler School of Medicine, Tel Aviv University, Tel Aviv 52621, Israel.
Avishai E; National Hemophilia Center, Sheba Medical Center, Ramat Gan 52621, Israel.; Amalia Biron Research Institute of Thrombosis and Hemostasis, Sackler School of Medicine, Tel Aviv University, Tel Aviv 52621, Israel.
Levy-Mendelovich S; National Hemophilia Center, Sheba Medical Center, Ramat Gan 52621, Israel.; Amalia Biron Research Institute of Thrombosis and Hemostasis, Sackler School of Medicine, Tel Aviv University, Tel Aviv 52621, Israel.
Barg AA; National Hemophilia Center, Sheba Medical Center, Ramat Gan 52621, Israel.; Amalia Biron Research Institute of Thrombosis and Hemostasis, Sackler School of Medicine, Tel Aviv University, Tel Aviv 52621, Israel.
Martinowitz U; National Hemophilia Center, Sheba Medical Center, Ramat Gan 52621, Israel.
Babol-Pokora K; Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, 90-419 Lodz, Poland.
Mlynarski W; Department of Pediatrics, Oncology and Hematology, Medical University of Lodz, 90-419 Lodz, Poland.
Kenet G; National Hemophilia Center, Sheba Medical Center, Ramat Gan 52621, Israel.; Amalia Biron Research Institute of Thrombosis and Hemostasis, Sackler School of Medicine, Tel Aviv University, Tel Aviv 52621, Israel.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Jul 24; Vol. 24 (14). Date of Electronic Publication: 2023 Jul 24.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Hemophilia A*/diagnosis
Hemophilia A*/genetics
Humans ; Pregnancy ; Female ; Factor VIII/genetics ; Prenatal Diagnosis/methods ; Genetic Carrier Screening ; Mutation ; Heterozygote

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 49.

Tytuł:: Augmented Degradation of Factors VIII and IX in the Intermittent Movement State.
Autorzy:: Cohen H; Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Health Care Campus, Haifa P.O. Box 9602, Israel.; The Rappaport Faculty of Medicine, Technion, Haifa P.O. Box 9602, Israel.
Keren-Politansky A; Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Health Care Campus, Haifa P.O. Box 9602, Israel.; The Rappaport Faculty of Medicine, Technion, Haifa P.O. Box 9602, Israel.
Crispel Y; Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Health Care Campus, Haifa P.O. Box 9602, Israel.; The Rappaport Faculty of Medicine, Technion, Haifa P.O. Box 9602, Israel.
Yanovich C; Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Health Care Campus, Haifa P.O. Box 9602, Israel.; The Rappaport Faculty of Medicine, Technion, Haifa P.O. Box 9602, Israel.
Asayag K; Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Health Care Campus, Haifa P.O. Box 9602, Israel.; The Rappaport Faculty of Medicine, Technion, Haifa P.O. Box 9602, Israel.
Nadir Y; Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Health Care Campus, Haifa P.O. Box 9602, Israel.; The Rappaport Faculty of Medicine, Technion, Haifa P.O. Box 9602, Israel.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Jun 27; Vol. 24 (13). Date of Electronic Publication: 2023 Jun 27.
Typ publikacji:: Journal Article
MeSH Terms:: Hemostatics*
Hemophilia A*/metabolism
Animals ; Mice ; Factor VIII/metabolism ; Factor IX/metabolism ; Thrombin ; Hemorrhage

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 50.

Tytuł:: In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
Autorzy:: Hemşinlioğlu C; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye; Biruni University, Department of Molecular Biology and Medical Genetics, İstanbul, Türkiye
Aslan ES; Biruni University, Department of Molecular Biology and Medical Genetics, İstanbul, Türkiye
Taştan C; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye; Üsküdar University, Department of Molecular Biology and Genetics, İstanbul, Türkiye; Üsküdar University, Transgenic Cell Technologies and Epigenetic Application and Research Center (TRGENMER), İstanbul, Türkiye
Çakırsoy D; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye; Institute of Karolinska, Department of Medicine, Stockholm, Sweden
Turan RD; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye; Yeditepe University, Department of Biotechnology, İstanbul, Türkiye; Yeditepe University, Cell and Gene Therapy Center of Excellence, İstanbul, Türkiye
Seyis U; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye
Elek M; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye; Yeditepe University, Department of Biotechnology, İstanbul, Türkiye
Sır Karakuş G; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye
Günaydın ÖS; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye
Abanuz S; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye; Acıbadem Mehmet Ali Aydınlar University, Department of Medical Biochemistry, İstanbul, Türkiye
Kançağı DD; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye
Yurtsever B; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye
Yalçın K; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye; Medical Park Göztepe Hospital, Pediatric Bone Marrow Transplantation Unit, İstanbul, Türkiye; Acıbadem Mehmet Ali Aydınlar University, Department of Medical Biotechnology, İstanbul, Türkiye
Kasap M; Kocaeli University Medical School, Department of Medical Biology, Kocaeli, Türkiye
Ovalı E; Acıbadem Labcell Cellular Therapy Laboratory, İstanbul, Türkiye; Pokaż więcej
Źródło:: Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2023 May 29; Vol. 40 (2), pp. 118-124. Date of Electronic Publication: 2023 Apr 06.
Typ publikacji:: Journal Article
MeSH Terms:: Hemophilia A*/genetics
Hemophilia A*/therapy
Mesenchymal Stem Cells*/metabolism
Animals ; Humans ; Factor VIII/genetics ; Blood Coagulation ; Genetic Therapy/methods

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 51.

Tytuł:: The Relationship Between the Energization of Moon‐Originating Ions and Terrain Type on the Lunar Surface.
Autorzy:: Lee, Jae‐Hee (AUTHOR)
Kim, Khan‐Hyuk (AUTHOR)
Baek, Seul‐Min (AUTHOR)
Jin, Ho (AUTHOR)
Saito, Yoshifumi (AUTHOR)
Nishino, Masaki N. (AUTHOR)
Yokota, Shoichiro (AUTHOR); Pokaż więcej
Temat:: Zenith distance
Ions
Ion energy
Lunar surface
Blood coagulation factor VIII
Źródło:: Journal of Geophysical Research. Space Physics. Mar2024, Vol. 129 Issue 3, p1-13. 13p.

Czasopismo naukowe

na półce

Szczegóły

Skocz do pozycji: 52.

Tytuł:: Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with severe hemophilia A.
Autorzy:: Huang K; Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Zhen Y; Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Li G; Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Wu X; Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Wu R; Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.
Chen Z; Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing, China.; Pokaż więcej
Źródło:: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 May; Vol. 27 (3), pp. e340-e346. Date of Electronic Publication: 2021 Mar 01.
Typ publikacji:: Journal Article
MeSH Terms:: Factor VIII*/pharmacokinetics
Factor VIII*/therapeutic use
Hemophilia A*/drug therapy
Child ; Half-Life ; Humans ; Male ; von Willebrand Factor

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 53.

Tytuł:: Assessing the value of bypassing agent therapy used prophylactic versus on-demand, during immune tolerance induction for treatment of inhibitors: a retrospective chart review.
Autorzy:: Morgan, George (AUTHOR)
Back, Emily (AUTHOR)
Rosa, Doug (AUTHOR)
O'Hara, Jamie (AUTHOR)
Finnegan, Alan (AUTHOR); Pokaż więcej
Źródło:: Orphanet Journal of Rare Diseases. 3/7/2023, Vol. 18 Issue 1, p1-8. 8p.

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 54.

Tytuł:: Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors.
Autorzy:: Lunghi B; Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Morfini M; Italian Association of Hemophilia Centers (AICE), Naples, Italy.
Martinelli N; Department of Medicine, University of Verona, Verona, Italy.
Branchini A; Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Linari S; Center for Bleeding Disorders, Department of Oncology, Careggi University Hospital, Florence, Italy.
Castaman G; Center for Bleeding Disorders, Department of Oncology, Careggi University Hospital, Florence, Italy.
Bernardi F; Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.; Pokaż więcej
Źródło:: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2023 Mar; Vol. 29 (2), pp. 479-487. Date of Electronic Publication: 2022 Dec 19.
Typ publikacji:: Journal Article
MeSH Terms:: Hemostatics*
Hemophilia A*/drug therapy
Hemophilia A*/genetics
Humans ; Factor VIII/genetics ; Factor VIII/pharmacokinetics ; von Willebrand Factor/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 55.

Tytuł:: Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A.
Autorzy:: Astermark J; Department of Translational Medicine, Lund University, Malmö, Sweden.; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.
Olsson A; Department of Medicine, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
Chelle P; School of Pharmacy, University of Waterloo, Waterloo, Canada.
Täckström K; Octapharma Nordic AB, Stockholm, Sweden.
Walger M; Octapharma Nordic AB, Stockholm, Sweden.
Magnusson M; Karolinska Institutet, Coagulation Unit, Department of Hematology, Department of Pediatrics, CLINTEC, Clinical Chemistry & Coagulation, MMK, Karolinska University Hospital, Stockholm, Sweden.
Iorio A; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.; Department of Medicine, McMaster University, Hamilton, ON, Canada.; Pokaż więcej
Źródło:: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Jul; Vol. 27 (4), pp. 626-633. Date of Electronic Publication: 2021 May 09.
Typ publikacji:: Journal Article
MeSH Terms:: Factor VIII*/pharmacokinetics
Factor VIII*/therapeutic use
Hemophilia A*/drug therapy
Hemostatics*/pharmacokinetics
Hemostatics*/therapeutic use
Adult ; Blood Specimen Collection ; Half-Life ; Humans

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 56.

Tytuł:: Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A.
Autorzy:: Santagostino E; Foundation IRCCS Ca' Granda, Maggiore Hospital Policlinico A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
Lalezari S; Israel National Hemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, Israel.; Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, Israel.
Reding MT; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, MN, USA.
Ducore J; Hemophilia Treatment Center, UC Davis Medical Center, Sacramento, CA, USA.
Ng HJ; Department of Haematology, Singapore General Hospital, Singapore.
Poulsen LH; The Haemophilia Centre, Aarhus University Hospital, Aarhus, Denmark.
Michaels LA; Bayer, Whippany, NJ, USA.
Linardi C; Bayer, Whippany, NJ, USA.; Pokaż więcej
Źródło:: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Jul; Vol. 27 (4), pp. e559-e562. Date of Electronic Publication: 2021 May 03.
Typ publikacji:: Letter
MeSH Terms:: Factor VIII*/therapeutic use
Hemophilia A*/drug therapy
Half-Life ; Humans ; Minor Surgical Procedures ; Polyethylene Glycols ; Treatment Outcome

Opinia redakcyjna

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 57.

Tytuł:: Protein residue network analysis reveals fundamental properties of the human coagulation factor VIII.
Autorzy:: Lopes TJS; Department of Reproductive Biology, Center for Regenerative Medicine, National Center for Child Health and Development Research Institute, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. .
Rios R; Department of Computer Science, Federal University of Bahia, Salvador, Brazil.; Institute of Mathematics and Computer Science, University of São Paulo, São Paulo, Brazil.
Nogueira T; Department of Computer Science, Federal University of Bahia, Salvador, Brazil.; Institute of Mathematics and Computer Science, University of São Paulo, São Paulo, Brazil.
Mello RF; Institute of Mathematics and Computer Science, University of São Paulo, São Paulo, Brazil.; Itaú Unibanco, Av. Eng. Armando de Arruda Pereira, 707, Jabaquara, São Paulo, 04309-010, Brazil.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2021 Jun 16; Vol. 11 (1), pp. 12625. Date of Electronic Publication: 2021 Jun 16.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Mutation*
Factor VIII/*chemistry
Factor VIII/*genetics
Hemophilia A/*metabolism
Amino Acid Motifs ; Binding Sites ; Factor VIII/metabolism ; Hemophilia A/genetics ; Humans ; Machine Learning ; Models, Molecular ; Protein Conformation ; Protein Stability

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 58.

Tytuł:: Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays.
Autorzy:: Augustsson C; Department of Clinical Chemistry and Pharmacology, Division of Laboratory Medicine, Coagulation, University and Regional Laboratories Region Skåne, Malmö, Sweden.
Norström E; Department of Translational Medicine, Lund University, Malmö, Sweden.
Lind V; Department of Clinical Chemistry and Pharmacology, Division of Laboratory Medicine, Coagulation, University and Regional Laboratories Region Skåne, Malmö, Sweden.
Martin M; Department of Clinical Chemistry and Pharmacology, Division of Laboratory Medicine, Coagulation, University and Regional Laboratories Region Skåne, Malmö, Sweden.
Astermark J; Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, and Department of Translational Medicine, Lund University, Malmö, Sweden.
Strandberg K; Department of Clinical Chemistry and Pharmacology, Division of Laboratory Medicine, Coagulation, University and Regional Laboratories Region Skåne, Malmö, Sweden.; Pokaż więcej
Źródło:: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 May; Vol. 27 (3), pp. 494-500. Date of Electronic Publication: 2021 Apr 18.
Typ publikacji:: Journal Article
MeSH Terms:: Factor VIII*/pharmacokinetics
Hemophilia A*/drug therapy
Blood Coagulation Tests ; Half-Life ; Humans ; Thrombin

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 59.

Tytuł:: Factor VIII concentrate dosing with lean body mass, ideal body weight and total body weight in overweight and obesity: A randomized, controlled, open-label, 3 × 3 crossover trial.
Autorzy:: Seaman CD; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA.
Yabes JG; Center for Research on Health Care Data Center, University of Pittsburgh, Pittsburgh, PA, USA.
Lalama CM; Center for Research on Health Care Data Center, University of Pittsburgh, Pittsburgh, PA, USA.
Ragni MV; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA.; Pokaż więcej
Źródło:: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 May; Vol. 27 (3), pp. 351-357. Date of Electronic Publication: 2021 Mar 22.
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Factor VIII*
Hemophilia A*/drug therapy
Adult ; Body Weight ; Cross-Over Studies ; Humans ; Ideal Body Weight ; Male ; Obesity/complications ; Overweight/complications

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 60.

Tytuł:: Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: Results from the Italian national registry.
Autorzy:: Cortesi PA; Value-Based Healthcare Unit, IRCCS MultiMedica, Sesto San Giovanni, Italy.; Research Centre on Public Health (CESP), University of Milan-Bicocca, Monza, Italy.
Giampaolo A; Department of Oncology and Molecular Medicine, Italian National Institute of Health, Rome, Italy.
Abbonizio F; Department of Oncology and Molecular Medicine, Italian National Institute of Health, Rome, Italy.
Molinari AC; Regional Reference Center for Hemorrhagic Diseases, Giannina Gaslini Institute, Genova, Italy.
Castaman G; Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.
Biffoni M; Department of Oncology and Molecular Medicine, Italian National Institute of Health, Rome, Italy.
Mantovani LG; Value-Based Healthcare Unit, IRCCS MultiMedica, Sesto San Giovanni, Italy.; Research Centre on Public Health (CESP), University of Milan-Bicocca, Monza, Italy.; Pokaż więcej
Źródło:: European journal of haematology [Eur J Haematol] 2021 Oct; Vol. 107 (4), pp. 408-415. Date of Electronic Publication: 2021 Jun 22.
Typ publikacji:: Journal Article
MeSH Terms:: Registries*
Chemoprevention/*methods
Drug Costs/*statistics & numerical data
Factor VIII/*therapeutic use
Hemophilia A/*drug therapy
Precision Medicine/*methods
Adolescent ; Adult ; Age Factors ; Chemoprevention/economics ; Child ; Child, Preschool ; Drug Administration Schedule ; Factor VIII/economics ; Female ; Hemophilia A/blood ; Hemophilia A/economics ; Hemophilia A/pathology ; Humans ; Infant ; Infant, Newborn ; Italy ; Male ; Precision Medicine/economics ; Severity of Illness Index

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Factor VIII"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język

Rok publikacji